Penn State Behrend Health and Wellness Center
Bacterial vaginosis (BV) is the most common cause of vaginal discharge in women of
childbearing age. It occurs when there is a complex change in the number and types of bacteria in the vagina.
Risk factors for BV include multiple or new sexual partners, douching, and cigarette smoking.
Although sexual activity is a risk factor for the condition, BV can occur in women who have never had vaginal intercourse. BV is not thought to be a sexually transmitted infection.
Approximately 50 to 75 percent of women with BV have no symptoms. Those with symptoms
often note an unpleasant, "fishy smelling" vaginal discharge that is more noticeable after sexual intercourse. Vaginal discharge that is off-white and thin may also be present.
A woman with concerns about excessive or foul-smelling vaginal discharge, abnormal
bleeding, or vulvar irritation is advised to see a healthcare provider. Self-treatment with over-the-counter products (eg, yeast creams, deodorants) is not recommended without a definite diagnosis.
BV is diagnosed with a physical examination and laboratory testing. The physical
examination usually includes a pelvic examination, which allows the healthcare provider to observe and test vaginal secretions during or immediately after the examination.
Treatment is usually recommended for women who have bothersome symptoms from the
infection and those preparing for abortion or hysterectomy. Treatment of BV may also reduce the risk of acquiring other STDs, including HIV. For this reason, some experts now support the concept of treating all women with BV.
There are two prescription medications used for the treatment of BV: metronidazole and
clindamycin. Both medications can be taken in pill form by mouth, or with a treatment inserted inside the vagina. Oral medication may be more convenient, but has a higher rate of side effects. Follow-up testing is not needed if symptoms resolve.
It is not necessary to treat the male sexual partner of a woman with BV; there is no evidence
that the woman's symptoms or risk of relapse is improved if her sex partner(s) is treated.
Approximately 30 percent of women who initially improve with standard treatment have a
recurrence of BV symptoms within three months, and more than 50 percent experience a recurrence within 12 months. Relapse can be treated with a prolonged course of oral or vaginal metronidazole or clindamycin for 10 to 14 days. Most women with recurrent BV benefit from suppressive therapy. A long-term maintenance regimen that includes vaginal metronidazole gel twice weekly may be of benefit, although secondary yeast infection can develop with this regimen.
Pregnant women with signs or symptoms of BV infection are usually treated to relieve
symptoms. Oral treatment with seven days of metronidazole is preferred over shorter oral regimens or vaginal treatments.
WHERE TO GET MORE INFORMATION
— Your healthcare provider is the best source of
information for questions and concerns related to your medical problem. Because no two patients
are exactly alike and recommendations can vary from one person to another, it is important to seek
guidance from a provider who is familiar with your individual situation.
Appointments can be made in person or by phone. If you are unable to keep your appointment, please call and
cancel. Otherwise you will be charged for the visit.
To schedule or cancel appointments, call: (814) 898-6217
For more information about health care issues, visit the Health and Wellness Center Web site at
This publication is available in alternative media on request.
Soc_Abstinence_010103 Approved by Patient Education Committee: 01/01/03
This content is reviewed periodically and is subject to change as new health information becomes available.
This information is intended to inform and educate and is not a replacement for medical evaluation, advice,
diagnosis or treatment by a healthcare professional.
Instructions: Do your work and record your results on separate paper. You can work on theproblems in any order. Clearly number your work for each problem. You do not need to writeanswers on the question sheet. This exam is a tool to help me (and you) assess how well you are learning the course material. As such, you should report enough written detail for me to understand how you are thinkingabo
______________________________________________________________________________ Media Contacts: Pam Eisele MSD Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin WHITEHOUSE STATION, N.J., July 26, 2013 – Merck Sharpe and Dohme (MSD), known as Merck in the United States and Canada, issued the following statement regarding the